Prospective Cohort Study of Intravenous Lipid Emulsion for Resuscitating Critically-ill Poisoned Patients

The purpose of this project is to evaluate the case characteristics of patients who receive intravenous lipid emulsion therapy. Previous literature to date has focused on animal studies or has been primarily limited to case reports or small case series. This prospectively collected data set will permit a much more detailed description of the use of lipid, its potential benefits, and potential harms.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Overdose Chemically-Induced Disorders Drug Misuse Drug Overdose Mental Disorders Prescription Drug Misuse Substance-Related Disorders

Sex eligibility

All sexes

Study type

Observational

Primary location

ACMT; ToxIC participating sites, Phoenix, Arizona, United States

About this study

The purpose of this project is to evaluate the case characteristics of patients who receive intravenous lipid emulsion therapy. A secondary objective is to determine the mortality in this critically ill population of individuals.

Previous literature to date has focused on animal studies or has been primarily limited to case reports or small case series. This prospectively collected data set will permit a much more detailed description of the use of lipid, its potential benefits, and potential harms.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

receiving intravenous lipid emulsion for treatment of a drug toxicity
Evaluation of a medical toxicologist as part of the ToxIC registry consortium

Exclusion criteria

not evaluated by a medical toxicologist participating in ToxIC

Treatment and study plan

administration of intravenous lipid emulsion

Other

all patients receive intravenous lipid emulsion at the discretion of the treating provider. This registry prospectively collects detailed information on such patients

Primary outcomes

Survival

Time frame: Survival is measured at hospital discharge. The study is open to enrollment indefinitely. It is estimated approximately 100 subjects will be enrolled in 5 years

The primary objective is to compare survival based on lipophilicity (as measured by LogD) of the drugs

Sponsors and collaborators

Lead sponsor

University of Southern California

Other

Collaborators

American College of Medical Toxicology

Registry information

Important dates

Study start: 2012
Primary completion: 2018
Study completion: 2018
First posted: Apr 11, 2017
Registry last updated: Mar 1, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed